Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Citizens has reiterated its Market Outperform rating and $6.00 price target on Taysha Gene Therapies (NASDAQ:TSHA), highlighting the company’s potential in treating Rett syndrome. The stock, currently trading at $4.88, has shown remarkable momentum with a 10.41% gain in the past week. According to InvestingPro data, analyst targets range from $5 to $14, suggesting significant upside potential.
The investment firm cited Taysha’s efficacy in Rett syndrome treatment, clean non-systemic safety profile, and regulatory clarity as key factors supporting its positive outlook on the stock.
Citizens noted important differences between Taysha and competitor Neurogene in their Rett gene therapy clinical strategies, particularly in administration routes, with Taysha using intrathecal lumbar (IT-L) delivery while Neurogene employs intracerebrovascular (ICV) administration.
The firm suggested Taysha may have a slight advantage regarding administration route due to the more involved procedure required for Neurogene’s ICV approach.
Both companies’ assets appear to successfully deliver gene therapy to critical brain structures and produce clinical effects, according to Citizens’ analysis of the available clinical data.
In other recent news, Taysha Gene Therapies has made significant advancements with its gene therapy for Rett syndrome. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to Taysha’s TSHA-102 treatment, following clinical evidence from Part A of the REVEAL Phase 1/2 trials, which demonstrated a 100% response rate among 12 treated patients. This designation supports the planned Biologics License Application submission. Additionally, Taysha has finalized regulatory alignment with the FDA on the pivotal trial protocol and statistical analysis plan for TSHA-102.
In terms of analyst updates, Baird raised its price target for Taysha Gene Therapies from $7.00 to $12.00, maintaining an Outperform rating. Cantor Fitzgerald reiterated its Overweight rating with a $13.00 price target, citing the profound efficacy profile of TSHA-102. JMP Securities also maintained its Market Outperform rating and set a $6.00 price target, highlighting the consistent distribution of the gene therapy across the brain and spinal cord. These developments reflect growing confidence in Taysha’s potential impact in treating Rett syndrome.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.